1. Market Research
  2. > Pharmaceutical Market Trends
Harnessing Patient-Centricity to Drive Profitability

Harnessing Patient-Centricity to Drive Profitability

  • October 2017
  • ID: 5251965
  • Format: PDF
  • Firstword Pharma

Summary

Table of Contents

Most, if not all, pharma companies are slowly but surely transforming themselves into patient-centric organisations, but some are much further along the path than others. What have the pioneers done differently and what have they learned in the process? What does success look like? And can patient-centric performance be accurately measured or compared? Harnessing Patient Centricity to Drive Profitability takes a pragmatic view across the patient-centric landscape, drawing upon the experiences and input of leaders in the field and providing new ideas on how to evolve your patient-first mindset to the next level.

Discover on this page…
• Key themes covered in the report
• What you will learn from the report
• Detailed table of contents
• Research objectives and methodologies employed producing in the report

Reasons to buy this report

The promise of ’putting patients at the heart of everything we do’ sounds great, but what does it actually mean in practice? For some pharma companies, it has proved difficult to move forward from a handful of day-to-day patient activities and an oft-mentioned sentiment that is difficult to translate into meaningful results. But the real pioneers in this transformative area have made a significant step change.

To achieve patient-centricity (and start to see the benefits), there must be a cultural shift that touches all areas of the business and every stage in the drug lifecycle. Those who have thus far simply paid lip-service to an ideal are now starting to stand out –for the wrong reasons.

This report will enable you to…
• Understand why patient-centricity is critically important as well as the benefits it can deliver if goals are set and advanced correctly.
• Discover which companies are leading the way on patient-centricity and find out what they are doing to break new ground.
• Assess the internal and external barriers to progress and build a case for management commitment and investment in patient-centricity over the long-term.
• Gain insight into how the progress and performance of patient-centric initiatives can be monitored and measured to provide meaningful insight to senior management.
• Hear expert views on how patient-centricity could evolve plus how key issues such as use of data, regulatory clarity and accurate measurement can all be addressed.
• Learn about the top recommendations for success from the leaders in the field.

Table of Contents

Executive summary

Patient centricity overview
• Key insights
• There is not a consistent definition of patient centricity
• Patient centricity is seen as a critically important concept
• Patient centricity delivers genuine benefit for all stakeholders
The pharmaceutical industry is viewed as being relatively patient centric
• There are still many different approaches to patient centricity
• Developing products that satisfy patients’ needs is the key driver for patient centricity
• Considerable progress has been made but barriers remain
• There is a range of external barriers preventing greater patient centricity
• The key internal barrier is resistance to change

How companies address patient centricity
• Key findings
• Great strides have been made towards greater patient centricity
• Patient-centric goals are vital for companies to drive the concept forward
• The tangible outcomes of patient centricity vary depending on many factors
• There are several companies leading the way in patient centricity
• UCB has been driving patient centricity forward for several years
• Boehringer Ingelheim: taking bold steps to show its patient-centric credentials
• Companies with a single focus have found it more straightforward to implement the patient-centric approach
• Many companies are now including patients in assessment of clinical trial design and execution

Measuring patient centricity
• Key findings
• The measurement of patient centricity remains an elusive concept
• Companies have adapted existing tools to measure patient centricity
• Surveys remain a popular method to assess patient centricity
• Certain indicators can show how patient centric a company is
• Profitability of patient centricity is important but complicated to measure
• Employees need to be accountable for patient centricity for it to be a success

The future of patient centricity
• Key findings
• Patient centricity will evolve to become a more mature concept
• Data will enable a better understanding of patients’ needs
• Increasing regulatory clarity will overcome barriers to patient centricity
• Patients will expect better provision of information
• Accurate measurement of patient centricity will become an increasing focus
• Recommendations for success
• Gain senior management support to drive the culture change
• Objectively assess how patient centric a company is
• Patient centricity is more than putting patients at the heart of all a company does

Figures
• Figure 1: The three aspects of measuring patient centricity in clinical trials
• Figure 2: Key performance indicators for patient centricity

Research Methodology and Objectives
This qualitative report offers a unique insight into industry progress on patient-centricity. It includes a clear overview of current approaches and delves into the practicalities, strategies and barriers to meeting longer-term goals as well as recommendations for next steps.

The insights presented are based on in-depth interviews conducted between with 8 pharma industry experts, all of whom are at the forefront of patient-centricity. Three interviewees chose to remain anonymous. Findings are backed up by secondary research.
• Jason DeGoes, Head of Global Patient Solutions Team at Teva Pharmaceuticals
• Keri Yale, Director, Patient Advocacy and Professional Relations, Boehringer Ingelheim
• Dr Luther T Clark, Global Director, Scientific Medical and Patient Perspective, Office of the Chief Patient Office, Merck & Co., Inc.
• Jaye-Bea Smalley, Associate Director, Patient Advocacy and Professional Relations-Patient Engagement, Boehringer Ingelheim
• Danielle Derijcke, Global Patient Affairs Officer,UCB

Key questions explored in this report include:
• How is patient-centricity defined and do views differ on what it means?
• What key objectives and goals have pharma companies set regarding patient-centricity?
• What do successful patient centric initiatives and activities look like?
• What results can be expected from specific patient-centric tasks or activities?
• What are the tangible outcomes of patient-centricity and what KPIs can be used to assess success?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Antibody Partnering Terms and Agreements 2014-2021

  • $ 3495
  • May 2021
  • 1000 pages

The Global Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the ...

  • World
  • Healthcare
  • Pharmaceutical
  • Industry analysis

ref:plp2017

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on